Investigation into Select Medical's Board Actions
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 03 2026
0mins
Source: Globenewswire
- Merger Investigation: Bleichmar Fonti & Auld LLP is investigating potential breaches of fiduciary duties by Select Medical Holdings Corporation's board and senior management in connection with the company's pending sale for $16.50 per share, which may adversely affect shareholder interests.
- Shareholder Vote Schedule: The merger has been approved by a special committee of Select Medical's board, with a shareholder vote scheduled for June 26, 2026, which could limit shareholders' ability to investigate the fairness of the merger if approved.
- Executive Stock Arrangement: Post-merger, co-founder Robert A. Ortenzio and Senior Executive Vice President Martin F. Jackson are allowed to
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SEM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SEM
Wall Street analysts forecast SEM stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 16.660
Low
17.00
Averages
18.75
High
21.00
Current: 16.660
Low
17.00
Averages
18.75
High
21.00
About SEM
Select Medical Holdings Corporation operates critical illness recovery hospitals, rehabilitation hospitals, and outpatient rehabilitation clinics in the United States. Its segments include Critical Illness Recovery Hospital, Rehabilitation Hospital, and Outpatient Rehabilitation. Critical Illness Recovery Hospital segment consists of hospitals designed to serve the needs of patients recovering from critical illnesses, often with complex medical needs. It operates the majority of its critical illness recovery hospitals as a hospital within a hospital (an HIH). Rehabilitation Hospital segment serves patients that require intensive physical rehabilitation care. Outpatient Rehabilitation segment consists of clinics that provide physical, occupational, and speech rehabilitation services. It operates around 105 critical illness recovery hospitals in 29 states, 36 rehabilitation hospitals in 14 states, and 1,922 outpatient rehabilitation clinics in 39 states and the District of Columbia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigation Launched into Select Medical's Merger Deal
- Merger Announcement: On March 2, 2026, Select Medical announced its acquisition for $16.50 per share, led by co-founder Robert A. Ortenzio and senior executives, with ties to a private equity firm, raising potential shareholder concerns about conflicts of interest.
- Shareholder Rights Issues: The merger will convert all Select Medical shares into cash, but allows certain executives to rollover their stakes into the new entity, which excludes public shareholders, potentially leading to allegations of unfair treatment.
- Investigation Rationale: Bleichmar Fonti & Auld LLP is investigating whether Select Medical's board and management breached their fiduciary duties during the merger negotiations and public disclosures aimed at securing shareholder approval, which could impact the legitimacy of the deal.
- Voting Schedule: The merger requires shareholder approval, with a vote set for June 26, 2026, and if passed, it may limit shareholders' ability to further investigate the fairness of the transaction.
See More
Investor Rights Law Firm Investigates Merger Transactions
- Merger Investigation: Halper Sadeh LLC is investigating the merger between Brink's Company and NCR Atleos Corporation, where Brink's shareholders are expected to own approximately 78% of the combined entity, potentially impacting shareholder rights and future earnings.
- Cash Acquisition Proposal: Select Medical Holdings Corporation is being sold to a consortium led by its executives and directors for $16.50 per share in cash, which could significantly affect the financial interests of its shareholders.
- Shareholder Rights Protection: Halper Sadeh LLC encourages Brink's and NCR shareholders to contact them to discuss their legal rights and options, indicating a strong commitment to protecting investor interests that may lead to increased transaction compensation or additional disclosures.
- Legal Fee Arrangement: The law firm promises to handle related matters on a contingent fee basis without upfront costs, reducing legal risks for shareholders and enhancing their willingness to participate in the investigation.
See More
Investigation Launched into Select Medical Merger Deal
- Shareholder Rights Investigation: Johnson Fistel, PLLP has initiated an investigation into whether the board of Select Medical Holdings breached its fiduciary duties in connection with the proposed sale to a consortium led by Robert A. Ortenzio, aiming to protect shareholder interests.
- Merger Deal Details: On March 2, 2026, Select Medical announced a definitive merger agreement with Robert A. Ortenzio's consortium at a cash price of $16.50 per share, expected to close in mid-2026 pending shareholder and majority non-consortium approval.
- Impact on Shareholder Rights: If consummated, the transaction will privatize Select Medical, leading to its shares being delisted from the NYSE, raising concerns about the fair treatment of minority shareholders and the overall value of their investments.
- Law Firm Background: Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm that has recovered approximately $90.725 million for clients in securities class actions, demonstrating its effectiveness in advocating for investor rights and its significant influence in the legal landscape.
See More
Investigation into Select Medical's Acquisition Deal
- Acquisition Investigation: Bleichmar Fonti & Auld LLP is investigating whether Select Medical Holdings Corporation's board and senior management breached their fiduciary duties to shareholders in connection with the company's pending sale at $16.50 per share, potentially impacting shareholder interests.
- Acquisition Details: The deal is led by co-founder Robert A. Ortenzio and Senior Executive VP Martin F. Jackson, with certain executives allowed to rollover their shares into the post-merger entity, a privilege not extended to public shareholders, raising fairness concerns.
- Shareholder Voting Schedule: The merger has been approved by a special committee, with a shareholder vote set for June 26, 2026, and the merger could close shortly thereafter, limiting shareholders' ability to investigate the fairness of the deal.
- Legal Options for Shareholders: BFA encourages current shareholders to submit their information to explore legal options, with all representation on a contingency fee basis, indicating a commitment to protecting shareholder rights.
See More
Investigation Launched into Select Medical's Merger Deal
- Merger Announcement: On March 2, 2026, Select Medical disclosed its agreement to be acquired for $16.50 per share, led by co-founder Robert A. Ortenzio and other executives, with ties to a private equity firm, raising concerns about shareholder interests.
- Shareholder Rights Concerns: The merger will convert all Select Medical shares into cash, but select executives and their affiliates are allowed to rollover their stakes into the new entity, a move not extended to public shareholders, potentially questioning the fairness of the deal.
- Investigation Rationale: Bleichmar Fonti & Auld LLP is investigating whether Select Medical's board and senior management breached their fiduciary duties during the merger negotiations and disclosures, which could impact shareholder decision-making.
- Voting Timeline: The merger requires shareholder approval, with a vote scheduled for June 26, 2026; if the deal closes shortly after, it may limit shareholders' ability to further investigate the merger's fairness, increasing legal risks.
See More
Investigation into Select Medical's Board Actions
- Merger Investigation: Bleichmar Fonti & Auld LLP is investigating potential breaches of fiduciary duties by Select Medical Holdings Corporation's board and senior management in connection with the company's pending sale for $16.50 per share, which may adversely affect shareholder interests.
- Shareholder Vote Schedule: The merger has been approved by a special committee of Select Medical's board, with a shareholder vote scheduled for June 26, 2026, which could limit shareholders' ability to investigate the fairness of the merger if approved.
- Executive Stock Arrangement: Post-merger, co-founder Robert A. Ortenzio and Senior Executive Vice President Martin F. Jackson are allowed to
See More
Investigation Launched into Select Medical's Merger Deal
- Merger Announcement: On March 2, 2026, Select Medical announced its acquisition for $16.50 per share, led by co-founder Robert A. Ortenzio and senior executives, with ties to a private equity firm, raising potential shareholder concerns about conflicts of interest.
- Shareholder Rights Issues: The merger will convert all Select Medical shares into cash, but allows certain executives to rollover their stakes into the new entity, which excludes public shareholders, potentially leading to allegations of unfair treatment.
- Investigation Rationale: Bleichmar Fonti & Auld LLP is investigating whether Select Medical's board and management breached their fiduciary duties during the merger negotiations and public disclosures aimed at securing shareholder approval, which could impact the legitimacy of the deal.
- Voting Schedule: The merger requires shareholder approval, with a vote set for June 26, 2026, and if passed, it may limit shareholders' ability to further investigate the fairness of the transaction.
See More
Investor Rights Law Firm Investigates Merger Transactions
- Merger Investigation: Halper Sadeh LLC is investigating the merger between Brink's Company and NCR Atleos Corporation, where Brink's shareholders are expected to own approximately 78% of the combined entity, potentially impacting shareholder rights and future earnings.
- Cash Acquisition Proposal: Select Medical Holdings Corporation is being sold to a consortium led by its executives and directors for $16.50 per share in cash, which could significantly affect the financial interests of its shareholders.
- Shareholder Rights Protection: Halper Sadeh LLC encourages Brink's and NCR shareholders to contact them to discuss their legal rights and options, indicating a strong commitment to protecting investor interests that may lead to increased transaction compensation or additional disclosures.
- Legal Fee Arrangement: The law firm promises to handle related matters on a contingent fee basis without upfront costs, reducing legal risks for shareholders and enhancing their willingness to participate in the investigation.
See More
Investigation Launched into Select Medical Merger Deal
- Shareholder Rights Investigation: Johnson Fistel, PLLP has initiated an investigation into whether the board of Select Medical Holdings breached its fiduciary duties in connection with the proposed sale to a consortium led by Robert A. Ortenzio, aiming to protect shareholder interests.
- Merger Deal Details: On March 2, 2026, Select Medical announced a definitive merger agreement with Robert A. Ortenzio's consortium at a cash price of $16.50 per share, expected to close in mid-2026 pending shareholder and majority non-consortium approval.
- Impact on Shareholder Rights: If consummated, the transaction will privatize Select Medical, leading to its shares being delisted from the NYSE, raising concerns about the fair treatment of minority shareholders and the overall value of their investments.
- Law Firm Background: Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm that has recovered approximately $90.725 million for clients in securities class actions, demonstrating its effectiveness in advocating for investor rights and its significant influence in the legal landscape.
See More
Investigation into Select Medical's Acquisition Deal
- Acquisition Investigation: Bleichmar Fonti & Auld LLP is investigating whether Select Medical Holdings Corporation's board and senior management breached their fiduciary duties to shareholders in connection with the company's pending sale at $16.50 per share, potentially impacting shareholder interests.
- Acquisition Details: The deal is led by co-founder Robert A. Ortenzio and Senior Executive VP Martin F. Jackson, with certain executives allowed to rollover their shares into the post-merger entity, a privilege not extended to public shareholders, raising fairness concerns.
- Shareholder Voting Schedule: The merger has been approved by a special committee, with a shareholder vote set for June 26, 2026, and the merger could close shortly thereafter, limiting shareholders' ability to investigate the fairness of the deal.
- Legal Options for Shareholders: BFA encourages current shareholders to submit their information to explore legal options, with all representation on a contingency fee basis, indicating a commitment to protecting shareholder rights.
See More
Investigation Launched into Select Medical's Merger Deal
- Merger Announcement: On March 2, 2026, Select Medical disclosed its agreement to be acquired for $16.50 per share, led by co-founder Robert A. Ortenzio and other executives, with ties to a private equity firm, raising concerns about shareholder interests.
- Shareholder Rights Concerns: The merger will convert all Select Medical shares into cash, but select executives and their affiliates are allowed to rollover their stakes into the new entity, a move not extended to public shareholders, potentially questioning the fairness of the deal.
- Investigation Rationale: Bleichmar Fonti & Auld LLP is investigating whether Select Medical's board and senior management breached their fiduciary duties during the merger negotiations and disclosures, which could impact shareholder decision-making.
- Voting Timeline: The merger requires shareholder approval, with a vote scheduled for June 26, 2026; if the deal closes shortly after, it may limit shareholders' ability to further investigate the merger's fairness, increasing legal risks.
See More
Investigation into Select Medical's Board Actions
- Merger Investigation: Bleichmar Fonti & Auld LLP is investigating potential breaches of fiduciary duties by Select Medical Holdings Corporation's board and senior management in connection with the company's pending sale for $16.50 per share, which may adversely affect shareholder interests.
- Shareholder Vote Schedule: The merger has been approved by a special committee of Select Medical's board, with a shareholder vote scheduled for June 26, 2026, which could limit shareholders' ability to investigate the fairness of the merger if approved.
- Executive Stock Arrangement: Post-merger, co-founder Robert A. Ortenzio and Senior Executive Vice President Martin F. Jackson are allowed to
See More
